APPLE 2023 Archives - Page 2 of 4

Dr. Wai-Kay Seto: Balancing the Risks and Benefits of Long-Term HBV Treatment

By Mourabit Halima 2024.01.17

The World Health Organization (WHO) has set ambitious goals in its Action Plan for the Elimination of Viral Hepatitis: by 2030, the diagnosis rate for chronic hepatitis B (CHB) should reach 90%, the treatment rate for eligible patients should be 80%, new infections should decrease by 90%, and related deaths should decrease by 65%. However, recent data shows that in mainland China and Hong Kong, the diagnosis rates for CHB are only 19% and 27%, respectively, and the treatment rates are only 11% and 22%, respectively. Globally, the diagnosis and treatment rates for CHB are only 10% and 5%, respectively. Achieving WHO's 2030 goal of eliminating viral hepatitis as a public health threat remains a daunting challenge. At the 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023), Dr. Wai-Kay Seto from the University of Hong Kong, China, was invited to give a special report on the risks and benefits of long-term HBV treatment.

Congratulations! Dr. Jian Zhou has been elected as the President-elect of the Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE)

By Mourabit Halima 2024.01.17

From July 6th to 8th, 2023, the 13th annual meeting of the Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE) was held in Seoul, South Korea, with the participation of nearly 1000 experts and scholars in the field of liver cancer from around the world. The current President and internationally renowned hepatopancreatobiliary surgeon, Dr. Norihiro Kokudo, announced during the general assembly of APPLE members that Dr. Jian Zhou from Zhongshan Hospital, Fudan University, China, has been elected as the President-elect of APPLE through a vote by the APPLE Executive Council. Dr. Zhou expressed his gratitude upon his election, stating that he will uphold tradition, foster innovation, and strive to achieve breakthroughs in the diagnosis and treatment of liver cancer.

Dr. Zhaochong Zeng: Enhancing Efficiency and Reducing Burden – Latest Advances in Radiotherapy for Liver Cancer Treatment

By Mourabit Halima 2024.01.17

Stereotactic Body Radiotherapy (SBRT), as a novel radiotherapy technique, has achieved encouraging results in the treatment of liver cancer. It not only improves local tumor control but also reduces distant metastases caused by tumors. Additionally, it minimizes radiation therapy-related complications, enhancing the quality of life for patients after treatment. However, how to maximize the role of SBRT in comprehensive liver cancer treatment is a topic worthy of further exploration. At the 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023), Dr. Zhaochong Zeng and his team from Zhongshan Hospital, Fudan University, China, presented two studies selected for oral and poster presentations, focusing on improving the effectiveness of SBRT and reducing radiation therapy-related adverse reactions, which attracted significant attention at the conference. In this article, Dr. Zeng shares insights into these two studies.

Dr. Ming Zhao: Key Clinical Research in Hepatocellular Carcinoma

By Mourabit Halima 2024.01.17

From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) was held in Seoul, South Korea. Hepatocellular carcinoma (HCC) experts from around the world gathered to rekindle academic discussions on HCC's basics, clinical aspects, research, and technology offline. The conference featured the latest research results from over a thousand scholars representing more than 50 countries. In this publication, Dr. Ming Zhao from Sun Yat-sen University Cancer Center, China, offers insightful interpretations of the significant clinical research emerging from APPLE 2023 for the benefit of our readers.

Dr. Huichuan Sun: Focusing on the Asia-Pacific Region, Leading the Frontier – Exploring Breakthroughs in the Treatment of Hepatobiliary Tumor

By Peter W. PENG 2024.01.17

The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) recently concluded in Seoul, South Korea, bringing together top experts in liver and biliary system tumors from around the world to discuss clinical hot topics and challenges. Dr. Huichuan Sun from Zhongshan Hospital, Fudan University, China, shares and interprets the latest developments and frontiers, including the Asia-Pacific consensus and groundbreaking research with us.

Dr. Xinwei Wang: The Molecular Landscape and Clinical Significance of Liver Cancer

By Mourabit Halima 2024.01.17

Liver cancer is one of the most prevalent and deadliest cancers in China. Due to the low early diagnosis rate of liver cancer in clinical practice, treatment options such as radical liver resection and transplantation face significant limitations. In recent years, there has been a surge in liver cancer genomics research, providing new insights into early diagnosis, patient stratification, and treatment prognosis. From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Expert Conference (APPLE 2023) was held in Seoul, South Korea. During the conference, Dr. Xinwei Wang from the U.S. National Cancer Institute gave a special lecture on "The Molecular Landscape and Clinical Significance of Liver Cancer." Hepatology Digest had the privilege of inviting Dr. Wang to share recent significant developments in this research field and delve into the potential applications and prospects of liver cancer genomics research for early diagnosis and prognosis prediction.